With 11.12 million shares changed hands, the volume of the stock remained heavier than its average volume of 4.91 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.77 whereas the lowest price it dropped to was $3.14. The 52-week range on PHIO shows that it touched its highest point at $10.35 and its lowest point at $1.53 during that stretch. It currently has a 1-year price target of $36.00. Beta for the stock currently stands at 1.19.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PHIO was up-trending over the past week, with a rise of 94.57%, but this was up by 32.59% over a month. Three-month performance surged to 33.58% while six-month performance fell -23.34%. The stock lost -43.17% in the past year, while it has gained 98.89% so far this year.
Float and Shares Shorts:
At present, 1.73 million PHIO shares are outstanding with a float of 1.68 million shares on hand for trading. On 2024-10-31, short shares totaled 51491.0, which was 598.0 higher than short shares on 1727654400. In addition to Mr. Robert J. Bitterman as the firm’s President, CEO & Chairman, Mr. Robert M. Infarinato CPA, Esq. serves as its CFO & Principal Accounting Officer.
Institutional Ownership:
Through their ownership of 0.03022 of PHIO’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, PHIO reported revenue of $0.0 and operating income of -$1590000.0. The EBITDA in the recently reported quarter was -$1590000.0 and diluted EPS was -$1.54.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
Analysts have provided yearly estimates in a range of -$16.38 being high and -$16.38 being low. For PHIO, this leads to a yearly average estimate of -$16.38. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
